TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22168946

Group type: EXPERIMENTAL
Intervention: Process-oriented training program for midwives and postnatal nurses (n=206)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group A (CGA) (n=162)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group B (CGB) (n=172)
Number of subjects: 540
Study: 19653488

Group type: EXPERIMENTAL
Intervention: Using a cell phone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not using a cell phone
Number of subjects: 0
Study: 17557985

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) high in catechins (583 mg of catechins per day)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (96 mg of catechins per day)
Number of subjects: 240
Study: 15161992

Group type: EXPERIMENTAL
Intervention: Moderately early dexamethasone (MED) group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Early dexamethasone (ED) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 12189112

Group type: EXPERIMENTAL
Intervention: bisoprolol (5 mg/d)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: enalapril (10 mg/d)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: nifedipine retard (20 mg/day)
Number of subjects: 331
Study: 9815204

Group type: EXPERIMENTAL
Intervention: Natural rotavirus infection (symptomatic infection)
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Initial symptomatic infection (placebo group)
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Initial serotype G3 episode (placebo group)
Number of subjects: 1185
Study: 7661122

Group type: EXPERIMENTAL
Intervention: 90 mg beta-carotene daily for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 120 mg beta-carotene oral dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: No beta-carotene
Number of subjects: 0
Study: 2649822

Group type: EXPERIMENTAL
Intervention: Laser vaporization
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laser excision conization
Number of subjects: 100
Study: 1096541

Group type: EXPERIMENTAL
Intervention: Penfluridol (peroral)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Flupenthixol decanoate (parenteral)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both drugs (penfluridol and flupenthixol decanoate)
Number of subjects: 56
Study: 31068212

Group type: EXPERIMENTAL
Intervention: High positive end-expiratory pressure (PEEP) during one-lung ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low positive end-expiratory pressure (PEEP) during one-lung ventilation
Number of subjects: 0
Study: 28488937

Group type: EXPERIMENTAL
Intervention: Conventional balance training
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Slackline training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 43
Study: 25950433

Group type: EXPERIMENTAL
Intervention: 2011/12 seasonal influenza DNA vaccine prime
Number of subjects: 131

Group type: COMPARATOR
Intervention: Phosphate buffered saline (PBS)
Number of subjects: 131
Study: 23384589

Group type: EXPERIMENTAL
Intervention: Ongoing contact through follow-up telephone calls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Providing collaterals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Receiving more than four telephone calls
Number of subjects: 0
Study: 21563210

Group type: EXPERIMENTAL
Intervention: Anticholinergic medication with or without behavioral therapy
Number of subjects: 307
Study: 18698222

Group type: COMPARATOR
Intervention: Lisinopril 40 mg
Number of subjects: 133

Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Valsartan/Lisinopril 320/20 mg
Number of subjects: 133
Study: 17138309

Group type: EXPERIMENTAL
Intervention: Pre-demonstration contact with test stimuli
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Post-demonstration contact with test stimuli
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Deferred imitation paradigm
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elicited imitation paradigm
Number of subjects: 50
Study: 14743888

Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin in combination with 5-fluoro-uracil (5-FU) and leucovorin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral prodrugs of 5-FU (capecitabine and uracil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies and small molecules targeting EGFR and VEGF
Number of subjects: 0
Study: 10899744

Group type: EXPERIMENTAL
Intervention: 2 x 300 mg extractum Valerianae radix siccum dragées LI 156
Number of subjects: 75

Group type: COMPARATOR
Intervention: 2 x 5 mg oxazepam dragées
Number of subjects: 75
Study: 8970248

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% solution
Number of subjects: 206

Group type: COMPARATOR
Intervention: Betaxolol 0.25% suspension
Number of subjects: 206
Study: 1471517

Group type: EXPERIMENTAL
Intervention: Piroxicam + Buprenorphine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Buprenorphine alone
Number of subjects: 81
Study: 6344893

Group type: EXPERIMENTAL
Intervention: Indoprofen 100 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Indoprofen 200 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Indoprofen 400 mg (i.v. bolus + 2-h infusion)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Indoprofen 400 mg (i.v. bolus alone)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31160812

Group type: EXPERIMENTAL
Intervention: Closed-loop digital meditation (MediTrain) delivered on mobile devices for 6 weeks
Number of subjects: 0
Study: 28898688

Group type: EXPERIMENTAL
Intervention: Decision support mobile digital platform
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 26420269

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (dorsolateral prefrontal cortex group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (cingulo-opercular network group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (motor primary cortex group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study: 24144788

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily with concomitant aspirin
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin with concomitant aspirin
Number of subjects: 18201

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily without concomitant aspirin
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin without concomitant aspirin
Number of subjects: 18201
Study: 23226553

Group type: EXPERIMENTAL
Intervention: FIFA 11+
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HarmoKnee
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 19157997

Group type: EXPERIMENTAL
Intervention: RU38486 (mifepristone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internal standard (alfaxolone)
Number of subjects: 0
Study: 17466461

Group type: EXPERIMENTAL
Intervention: BRT protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine burn rehabilitation treatment
Number of subjects: 0
Study: 15894098

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery
Number of subjects: 794

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 794
Study: 9711448

Group type: EXPERIMENTAL
Intervention: Orlistat 360 mg/day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study: 7883739

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study: 2677374

Group type: EXPERIMENTAL
Intervention: H142 at 1.0 mg/kg/h
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: H142 at 2.5 mg/kg/h
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: H142 at 5.0 mg/kg/h
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: H142 (all doses)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: H142 (after stopping)
Number of subjects: 1
Study: 356925

Group type: EXPERIMENTAL
Intervention: multivitamin‐electrolyte‐preparation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: B1, B2 and B6 deficiencies
Number of subjects: 40
Study: 30076614

Group type: EXPERIMENTAL
Intervention: Terlipressin (2-12 mg/day)
Number of subjects: 120
Study: 31007053

Group type: EXPERIMENTAL
Intervention: Group-based occupational therapy (Group BOT, n=43)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Group-based physiotherapy (Group BPT, n=42)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard rehabilitation programme only (Group A, n=96)
Number of subjects: 181
Study: 28027937

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 16
Study: 25998582

Group type: EXPERIMENTAL
Intervention: Tamsulosin 400 μg
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Tamsulosin vs Nifedipine
Number of subjects: 1136
Study: 23633761

Group type: EXPERIMENTAL
Intervention: MEMS-accelerometry
Number of subjects: 15
Study: 21309005

Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study: 19950087

Group type: EXPERIMENTAL
Intervention: PTRA + IVBT
Number of subjects: 71

Group type: COMPARATOR
Intervention: PTRA
Number of subjects: 71
Study: 17667835

Group type: EXPERIMENTAL
Intervention: Versajet system
Number of subjects: 87

Group type: COMPARATOR
Intervention: Hand-held dermatome escharectomy
Number of subjects: 87
Study: 15618271

Group type: EXPERIMENTAL
Intervention: H1 receptor antagonist (540 mg oral fexofenadine hydrochloride; Allegra)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no H1 receptor antagonist)
Number of subjects: 14
Study: 12518534

Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori infection using triple therapy (pantoprazole + amoxicillin + clarithromycin)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group with Helicobacter positive infection
Number of subjects: 97
Study: 9578506

Group type: EXPERIMENTAL
Intervention: GH therapy (18 units/m2 per week divided into daily s.c. doses) for 1 year
Number of subjects: 41

Group type: COMPARATOR
Intervention: GH response to provocation by clonidine and glucagon
Number of subjects: 41

Group type: COMPARATOR
Intervention: IGF‐I generation test after GH injection
Number of subjects: 41

Group type: COMPARATOR
Intervention: Correlation of serum ferritin concentration with GH peak response to provocation
Number of subjects: 41
Study: 7645033

Group type: EXPERIMENTAL
Intervention: MMF 2 g treatment group (1.0 g b.i.d.)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: MMF 3 g treatment group (1.5 g b.i.d.)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Azathioprine group (1-2 mg/kg/day)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: MMF 2 g treatment group
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: MMF 3 g treatment group
Number of subjects: 499

Group type: COMPARATOR
Intervention: Azathioprine group
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 499
Study: 2694923

Group type: EXPERIMENTAL
Intervention: 4 capsules (1.26 g omega-3 fatty acids)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 8 capsules (2.52 g omega-3 fatty acids)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose fish oil (4 capsules)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 582710

Group type: EXPERIMENTAL
Intervention: Indometacin (150 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glucametacin (420 mg daily)
Number of subjects: 40
Study: 31564841

Group type: EXPERIMENTAL
Intervention: 10-week progressive vigorous interval training program (3 times per week)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (maintained daily living and routines)
Number of subjects: 77
Study: 29523175

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27040455

Group type: EXPERIMENTAL
Intervention: 2D stored RBCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: 35D stored RBCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PS exposure, lactadherin binding, CD47 expression
Number of subjects: 0
Study: 25295437

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 245
Study: 22268518

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Pravastatin 10 mg
Number of subjects: 87
Study: 20072786

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 119
Study: 18095810

Group type: EXPERIMENTAL
Intervention: rHuPH20 150 U
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: rHuPH20 750 U
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: rHuPH20 1500 U
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline placebo (150 U)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline placebo (750 U)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline placebo (1500 U)
Number of subjects: 54
Study: 15692543

Group type: COMPARATOR
Intervention: Ketoprofen (100 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Celecoxib (200 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 11815543

Group type: EXPERIMENTAL
Intervention: Transfusions guided by peripheral FOE measurements (NIRS group)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Transfusions guided by conventional protocol based on Hb (conventional group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study: 10401920

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 7588829

Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg q 24h i.v.
Number of subjects: 174

Group type: COMPARATOR
Intervention: Gentamicin 1.33 mg/kg q 8h i.v. (thrice-daily)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Netilmicin 5.5 mg/kg q 24h i.v.
Number of subjects: 174
Study: 2378175

Group type: EXPERIMENTAL
Intervention: Intravenous pulse methylprednisolone 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous pulse methylprednisolone 250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both dosages of intravenous methylprednisolone
Number of subjects: 0
Study: 35399

Group type: EXPERIMENTAL
Intervention: Ypsilon-Y IUD
Number of subjects: 300

Group type: COMPARATOR
Intervention: Lippes Loop D
Number of subjects: 300
Study: 31801940

Group type: EXPERIMENTAL
Intervention: Ofatumumab (300 mg first week, followed by 1000 mg every 8 weeks for up to 2 years)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 480
Study: 27879176

Group type: EXPERIMENTAL
Intervention: Focus-of-attention behavioral experiment (FABE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Exposure-Only Control (EOC)
Number of subjects: 45
Study: 25703957

Group type: EXPERIMENTAL
Intervention: 16-session exercise-based rehabilitation program
Number of subjects: 20
Study: 23497636

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg idursulfase beta infusions
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg idursulfase beta infusions
Number of subjects: 31

Group type: COMPARATOR
Intervention: Active comparator infusions
Number of subjects: 31
Study: 21996523

Group type: EXPERIMENTAL
Intervention: Recombinant human factor VIIa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19634856

Group type: EXPERIMENTAL
Intervention: Cemented metal-on-metal THA
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cemented metal-on-polyethylene THA
Number of subjects: 200
Study: 16598490

Group type: EXPERIMENTAL
Intervention: Single-coated STAR
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Double-coated STAR
Number of subjects: 109

Group type: COMPARATOR
Intervention: Single-coated STAR (last 31 cases)
Number of subjects: 109
Study: 15182983

Group type: COMPARATOR
Intervention: Walking at predetermined velocities (0.17 to 1.72 m/s)
Number of subjects: 0
Study: 11255055

Group type: EXPERIMENTAL
Intervention: Temporal sclerocorneal incision
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clear corneal incision
Number of subjects: 100
Study: 9210530

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone supplementation (rhGH, 0.15 mg/kg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Total parenteral nutrition alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with adjuvant rhGH
Number of subjects: 24
Study: 8036601

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (in patients resistant to other immunodepressants)
Number of subjects: 43
Study: 3519885

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) plus aminoglutethimide (AG) and hydrocortisone (HC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) and hydrocortisone (HC) after TAM therapy
Number of subjects: 100
Study: 31698085

Group type: EXPERIMENTAL
Intervention: 1, 2, or 3 autodial reminders
Number of subjects: 120130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120130
Study: 29127492

Group type: EXPERIMENTAL
Intervention: 0.2 μg/kg dexmedetomidine (Dex-0.2 group)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg dexmedetomidine (Dex-0.5 group)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 137
Study: 25706950

Group type: EXPERIMENTAL
Intervention: FBT plus reduced variety of high energy-dense foods (FBT+Variety)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual family based treatment (FBT)
Number of subjects: 24
Study: 23237107

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day or 20 mg/day or atorvastatin 80 mg/day for 12 weeks
Number of subjects: 682
Study: 21040694

Group type: EXPERIMENTAL
Intervention: SC602 (1 × 10(6) CFU)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: SC602
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 18332052

Group type: EXPERIMENTAL
Intervention: Targeted multifactorial falls prevention programme
Number of subjects: 3999

Group type: COMPARATOR
Intervention: Control wards
Number of subjects: 3999
Study: 17178701

Group type: EXPERIMENTAL
Intervention: Orlistat plus hypocaloric diet
Number of subjects: 71

Group type: COMPARATOR
Intervention: Hypocaloric diet only
Number of subjects: 71
Study: 15556325

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg before surgery
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo injection before surgery
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg after surgery
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo injection after surgery
Number of subjects: 34
Study: 10895410

Group type: EXPERIMENTAL
Intervention: r-tPA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: TNK-tPA
Number of subjects: 39
Study: 9322804

Group type: EXPERIMENTAL
Intervention: 30 mg methimazole (MMI) + 1.5 micrograms 1 alpha (OH)D3 (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 30 mg methimazole (MMI) (group A)
Number of subjects: 30
Study: 7691269

Group type: EXPERIMENTAL
Intervention: 4-hydroperoxycyclophosphamide (4-HC) with WR-2721 (amifostine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive selection of CD34+ hematopoietic progenitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-hydroperoxycyclophosphamide (4-HC) alone
Number of subjects: 0
Study: 3531038

Group type: EXPERIMENTAL
Intervention: Endralazine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 20
Study: 30229852

Group type: EXPERIMENTAL
Intervention: rhPro-UK thrombolysis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (Solitaire scaffold)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined treatment (rhPro-UK after Solitaire scaffold)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thrombolysis group (rhPro-UK)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mechanical thrombectomy group (Solitaire scaffold)
Number of subjects: 90
Study: 26872105

Group type: EXPERIMENTAL
Intervention: Telecoaching
Number of subjects: 574

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 574
Study: 24924486

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day for six months
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 22778302

Group type: EXPERIMENTAL
Intervention: Exposure to cartoon movie with smoking characters
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Exposure to family-oriented movie with smoking characters
Number of subjects: 206

Group type: COMPARATOR
Intervention: Exposure to cartoon movie without smoking characters
Number of subjects: 206

Group type: COMPARATOR
Intervention: Exposure to family-oriented movie without smoking characters
Number of subjects: 206
Study: 20426883

Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 18693399

Group type: EXPERIMENTAL
Intervention: Care pathways (CP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0